4
Changes in Ownership
Oncotelic Therapeutics, Inc. Filed Acc 0001209191-18-024986
Chief Financial Officer bought 250,000 shares
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| LOAR MATTHEW M Chief Financial Officer | 2018-04-12 | Purchase | +250,000 | 300,000 | D | ||
| Derivatives | |||||||
| LOAR MATTHEW M Chief Financial Officer | 2018-04-12 | Purchase · Common Stock A Warrant (Right to Buy) | +125,000 | 125,000 | D | ||
| LOAR MATTHEW M Chief Financial Officer | 2018-04-12 | Purchase · Common Stock B Warrant (Right to Buy) | +125,000 | 125,000 | D | ||
| Open-market purchases · 250,000 sh | |||||||
Loading xslF345X03/doc4.xml…